Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10465360" target="_blank" >RIV/00064165:_____/22:10465360 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11110/22:10465360
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.32383/appdr/159470" target="_blank" >10.32383/appdr/159470</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation
Popis výsledku v původním jazyce
The prognosis for patients with acute myeloid leukemia (AML) varies depending on genetic factors. The presence of mutations in the FMS-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient's comfort during treatment. In general, it has a favorable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. This review aims to summarise the current knowledge on midostaurin, i.e. its mechanisms of action, dosage, adverse effects, mechanisms of resistance, and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The authors emphasize therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation.
Název v anglickém jazyce
Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation
Popis výsledku anglicky
The prognosis for patients with acute myeloid leukemia (AML) varies depending on genetic factors. The presence of mutations in the FMS-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient's comfort during treatment. In general, it has a favorable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. This review aims to summarise the current knowledge on midostaurin, i.e. its mechanisms of action, dosage, adverse effects, mechanisms of resistance, and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The authors emphasize therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Acta Poloniae Pharmaceutica
ISSN
0001-6837
e-ISSN
2353-5288
Svazek periodika
79
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
PL - Polská republika
Počet stran výsledku
8
Strana od-do
777-784
Kód UT WoS článku
000992684900001
EID výsledku v databázi Scopus
2-s2.0-85151408093